Abstract
Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 347-352 |
| Number of pages | 6 |
| Journal | Psychiatry Research |
| Volume | 198 |
| Issue number | 3 |
| DOIs | |
| State | Published - Aug 15 2012 |
Fingerprint
Keywords
- Drug-naïve
- Lipidomics
- Metabolomics
- Phospholipids
- Plasmalogen
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
Cite this
Impaired plasmalogens in patients with schizophrenia. / Kaddurah-Daouk, Rima; McEvoy, Joseph Patrick; Baillie, Rebecca; Zhu, Hongjie; K. Yao, Jeffrey; Nimgaonkar, Vishwajit L.; Buckley, Peter F; Keshavan, Matcheri S.; Georgiades, Anastasia; Nasrallah, Henry A.
In: Psychiatry Research, Vol. 198, No. 3, 15.08.2012, p. 347-352.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impaired plasmalogens in patients with schizophrenia
AU - Kaddurah-Daouk, Rima
AU - McEvoy, Joseph Patrick
AU - Baillie, Rebecca
AU - Zhu, Hongjie
AU - K. Yao, Jeffrey
AU - Nimgaonkar, Vishwajit L.
AU - Buckley, Peter F
AU - Keshavan, Matcheri S.
AU - Georgiades, Anastasia
AU - Nasrallah, Henry A.
PY - 2012/8/15
Y1 - 2012/8/15
N2 - Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.
AB - Plasmalogens are a subclass of glycerophospholipids and ubiquitous constituents of cellular membranes and serum lipoproteins. Several neurological disorders show decreased level of plasmogens. An earlier study found differences in plasma phospholipids between unmedicated patients with schizophrenia and matched healthy control subjects. We here report a comparison of plasma plasmalogen levels across 20 drug-naïve patients experiencing first psychotic episodes, 20 recently unmedicated patients experiencing psychotic relapses after failing to comply with prescribed medications, and 17 matched healthy control subjects. Multiple plasma phosphatidylcholine and phosphatidylethanolamine plasmalogen levels were significantly lower in first episode patients and patients with recurrent disease compared to healthy controls. Reduced plasmalogen levels appear to be a trait evident at the onset of psychotic illness and after multiple psychotic relapses. It is implied that reductions in plasmalogen levels are not related to antipsychotic treatment but due to the illness itself. Reduced plasmalogen levels suggest impairments in membrane structure and function in patients with schizophrenia that might happen early in development. This may serve as a clue to the neurobiology of schizophrenia and should be studied as a potential biomarker for individuals at risk for schizophrenia.
KW - Drug-naïve
KW - Lipidomics
KW - Metabolomics
KW - Phospholipids
KW - Plasmalogen
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84868642991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868642991&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2012.02.019
DO - 10.1016/j.psychres.2012.02.019
M3 - Article
C2 - 22513041
AN - SCOPUS:84868642991
VL - 198
SP - 347
EP - 352
JO - Psychiatry Research
JF - Psychiatry Research
SN - 0165-1781
IS - 3
ER -